This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

WCLC, YOKOHAMA, 15 - 18 OCTOBER 2017 - T790M

Prevalence of EGFR T790M mutation in NSCLC patients after afatinib failure, and subsequent response to osimertinib

Maximilian J. Hochmair, Sophia Schwab, Otto Burghuber, Renate Koger, Ulrike Setinek, Agnieszka Cseh, Richard Fritz, Anna Buder, Martin Filipits

Hochmair et al T790M EGFR WCLC 2017

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

Yu HA, et al. Clin Cancer Res 2013;19(8):2240–7

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Sequist LV, et al. Sci Transl Med 2011;3(75):75ra26

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

Wu SG, et al. Oncotarget 2016;7(11):12404–13

Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer

Mok TS, et al. N Engl J Med 2017;376(7):629–40

Subsequent therapies post-afatinib among patients with EGFRmutation-positive NSCLC in LUX-Lung (LL) 3, 6 and 7

Sequist LV, et al. ESMO 2017:1349P